Last checked at 25 Jun 2021 13:17
genedrive plc
("genedrive" or the "Company")
Genedrive confirms receipt of India Import License
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, notes the recent rise in its share price and confirms that it has received a license to import the Genedrive® SARS-CoV-2 Kit into India via its partner DIVOC Health. This step follows the approval of the product at the Indian Centre for Medical Research on 30 April 2021.
As previously stated, India has introduced pricing controls in their routine public testing market that favours the provision of lower cost/basic tests than the Genedrive SARS-Cov-2 Kit. The Company continues to assess specific commercial opportunities with DIVOC Health in the Indian public and private markets.
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO |
|
|
|
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel / Victoria Erskine |
|
|
|
finnCap (Joint Broker) | +44 (0)20 7220 0500 |
Geoff Nash / Kate Bannatyne / Alice Lane |
|
|
|
Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com)
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.